Analysis Regulatory

FDA's Global Reliance Disclosure Program: what minimally redacted approval packages mean for filings

FDA will share less-redacted approval packages with applicants for use abroad, starting with PEPFAR tentative approvals and widening to novel drugs and biologics in January 2027.

VigiEye editorial · Wed 18 Nov 2026

What happened

On 17 November 2026 FDA launched the Global Reliance Disclosure Program. Under it, applicants can obtain minimally redacted FDA approval packages to support filings with foreign regulators. The first phase covers PEPFAR tentative approvals. In January 2027 the scheme widens to novel drugs and biologics.

FDA frames the programme as a way to expand patient access to medicines worldwide. The published record does not say how applicants request a package, what the timelines are, whether fees apply, or which foreign authorities have agreed to accept the material. Those details are not yet known and will determine how useful the programme is in practice.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Sources this analysis is based on

Written by VigiEye's editorial system with AI assistance (model claude-sonnet-5-5) strictly from the official records listed above. It can contain errors: check the sources before acting. Not legal, medical or investment advice.

More analysis & opinionAll →